Tavapadon (Juvmo) is the first selective D1/D5 dopamine receptor agonist approved for adult Parkinson disease, positioning a mechanistically differentiated oral, once-daily dopaminergic strategy.

NEW HAVEN, Conn. (WTNH) — In today’s Health Headlines, is every tremor an indicator of Parkinson’s disease, and common myths about medications for Parkinson’s. What to know about treatments for gait ...

In a study published in eNeuro, Lena Ting, from Emory University, and colleagues explored how brain and muscle activity during balance recovery change due to aging and Parkinson's. Previously, Ting's ...

Sept 25 (Reuters) - The US Food and Drug Administration has approved AbbVie's treatment for Parkinson's disease in adults, ...

Basic knowledge for "treating the whole body," not just motor symptomsWhen you hear Parkinson's disease, you might first think of "hand tremors" or "difficulty walking." However, the important point ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

February 9, 2012 — Results of a randomized trial show that training patients with Parkinson's disease in the ancient art of tai chi reduced balance impairments, improving function and reducing falls. ...

Postdoctoral researcher Nancy Ahuja at the University of Oxford studies extracellular vesicle communication between neurons ...